 AIM ImmunoTech Inc NYSE:AIM has announced that the Netherlands Patent Office has granted the company a utility patent covering rugged dsRNA, a double-stranded RNA product related to its lead candidate Ampligen rintatolimod, which claims cover, among other aspects, compositions, and compositions for use in the prevention or treatment of COVID-19. The new patent broadens AIMs existing portfolio for COVID-19 treatments to include rugged dsRNA, the company said. 